Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Spersonalizowane leczenie tytoniowe w podstawowej opiece zdrowotnej

2 listopada 2026 zaktualizowane przez: Washington University School of Medicine

Wielopoziomowa interwencja mająca na celu personalizację i poprawę leczenia tytoniowego w podstawowej opiece zdrowotnej

This study examines the application of precision treatment intervention for smoking cessation from both the clinician perspective and patient perspective, and compares it to usual care on tobacco treatment in the primary care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This approach may increase effectiveness and adherence for the patient, and increase the clinician's likelihood of prescribing.

Przegląd badań

Szczegółowy opis

The overarching goal of this study is to test the impact of a multilevel precision treatment intervention aiming to address gaps in clinician and patient uptake of tobacco treatment and overall treatment effectiveness. This study builds on evidence that (1) genetic and metabolic factors may inform precision tobacco treatment and (2) increasingly high demand for precision treatment, in particular, may signal its potential to activate behavior change. The multilevel precision treatment intervention to be tested--PrecisionTx-- provides the opportunity to present personalized risk, benefit, and treatment recommendation to increase clinician ordering, patient uptake, and overall effectiveness of tobacco treatment. This study aims to understand the relative benefit of precision treatment over usual care and associated mechanistic and implementation outcomes. Therefore, the investigators propose a 2-arm cluster randomized controlled trial of 50 clinicians and 800 screen-eligible patients (~16 per clinician) from diverse primary care settings. Clinicians and patients will be randomized with 1:1 allocation to usual care (UC) vs. precision treatment (PT) to evaluate the effect of precision treatment on smoking cessation success. In Aim 1, the investigators will test the effect of PT on clinician prescribing (or patient receipt of medication when prescription is not needed) and patient use of medication for smoking cessation. The investigators hypothesize that patient receipt of tobacco treatment medication for smoking cessation at 6 months post-intervention will be higher in PT vs UC. The investigators also hypothesize that patient use of cessation medication at 6 months post-intervention will be higher in PT vs. UC. In Aim 2, the investigators will test the effect of PT on patient smoking abstinence. The investigators hypothesize that patient bioverified smoking abstinence at 6 months will be higher in PT vs. UC. In Aim 3, the investigators will examine mechanisms of behavior change and implementation outcomes. The investigators will evaluate putative mechanisms for PT (e.g., outcome expectancy and withdrawal suppression). The investigators will conduct assessments at baseline, intervention, and 1-month, 3-month, 6-month, and 12-month post-intervention follow-ups.

Primary outcomes include patient receipt of tobacco treatment, patient use of tobacco treatment, and patient smoking abstinence. Secondary outcomes include patient receipt of recommended medication, patient medication adherence, and additional patient smoking cessation outcomes. Mechanistic outcomes include clinician level (perceived benefit, outcome expectancy), clinician-patient interaction (self-efficacy), patient-level (perceived risk, outcome expectancy, withdrawal suppression, adverse events). Implementation outcomes will be evaluated based on the RE-AIM framework. The study is an innovative paradigm shift from a traditional treatment model to precision treatment that includes both metabolic and genetic markers to motivate and guide tobacco treatment for both clinicians and patients, integrated within primary care.

Smoking is a leading cause of premature death, causing more than half of all cancer deaths. However, tobacco treatment is often not provided and is not highly effective in primary care. New evidence suggests that a precision treatment approach to motivate and guide treatment based on personal genetic and metabolic markers could improve treatment uptake and quit success. This study will test the impact of a multilevel precision treatment intervention on improving tobacco treatment and health outcomes in primary care.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

850

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: Li-Shiun Chen, ScD, MD, MPH
  • Numer telefonu: 314-362-3932
  • E-mail: li-shiun@wustl.edu

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Missouri
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Rekrutacyjny
        • Washington University School of Medicine
        • Kontakt:
        • Kontakt:
        • Główny śledczy:
          • Li-Shiun Chen, ScD, MD, MPH
        • Główny śledczy:
          • Alex Ramsey, PhD
        • Pod-śledczy:
          • Laura Bierut, MD
        • Pod-śledczy:
          • Esther Lu, PhD
        • Pod-śledczy:
          • Robert Schnoll, PhD
        • Pod-śledczy:
          • Timothy Baker, PhD
        • Pod-śledczy:
          • Hilary Tindle, MD
        • Pod-śledczy:
          • Rachel Tyndale, PhD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Eligibility Criteria for Primary and Specialty Care Clinicians

  • Clinician from participating clinic
  • At least 18 years of age
  • Can speak and understand English

Eligibility Criteria for Primary Care and Specialty Patients

Inclusion:

  • Patient at participating clinic
  • Age 18 years or older, inclusive
  • Current smoking (cigarettes per day >=5)
  • Can speak and understand English
  • Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline

Exclusion:

  • Active use of smoking cessation medication (within the past 30 days)
  • Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)
  • Having a contraindication for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Usual Care

The arm will represent usual care in the primary care clinics. Physicians will receive a report designed to recommend guideline-based tobacco treatment. Patients will receive a report on guideline-based advice about smoking cessation and a brief discussion with a behavior interventionist.

Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).

Eksperymentalny: PrecisionTx

Physicians will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment. Patients will receive PrecisionTx, an intervention designed to recommend precision tobacco treatment, and a brief discussion with a behavior interventionist.

Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Patient receipt of tobacco treatment medication for smoking cessation
Ramy czasowe: 6 months post-intervention

This will be quantified by the proportion of enrolled patients who receive cessation medication.

6 months post-intervention
Patient use of cessation medication
Ramy czasowe: 6 months post-intervention

This will be quantified by the proportion of patients taking any cessation medication from time of enrollment through 6 months post-intervention.

6 months post-intervention
Patient smoking abstinence
Ramy czasowe: 6 months post-intervention

This will be quantified by the proportion of smokers with bioverified point-prevalent abstinence at 6 months.

6 months post-intervention

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Patient receipt of recommended tobacco treatment
Ramy czasowe: 6 months post-intervention

This will be quantified by the proportion of enrolled patients who received recommended cessation medication.

6 months post-intervention
Patient medication adherence
Ramy czasowe: 6 months post-intervention

This will be quantified by the proportion of medication taken among medication prescribed.

6 months post-intervention
Patient smoking abstinence among treated
Ramy czasowe: 6 months post-intervention

This will be quantified by the proportion of smokers with bioverified point-prevalence abstinence among those receiving cessation medication.

6 months post-intervention
Abstinence Outcomes Across Multiple Time Points
Ramy czasowe: From intervention through 12 months post-intervention

The outcome measures abstinence (self-reported no smoking (not even a puff of a cigarette) for at least 7 days prior to the assessment) over these time points.

From intervention through 12 months post-intervention
Smoking quantity across multiple time points
Ramy czasowe: From intervention through 12 months post-intervention

The outcome measures smoking quantity (self-reported average cigarettes smoked per day for the past 30 days prior to the assessment) over these time points.

From intervention through 12 months post-intervention
Quit attempts
Ramy czasowe: 6 and 12 months post-intervention

This outcome measures the number of quit attempts in the past 30 days prior to the assessment over these time points.

6 and 12 months post-intervention

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Perceived benefits (Clinician)
Ramy czasowe: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' perceived importance and benefits of patients receiving smoking cessation medications will be assessed using a modified version of the Beliefs and Attitudes About Bupropion Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Outcome expectancies (Clinician)
Ramy czasowe: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' outcome expectancies regarding tobacco treatment will be assessed using a modified version of the Stanford Expectation of Treatment Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Self-efficacy regarding patient-clinician interaction (Clinician)
Ramy czasowe: Exit interview [after clinician has been enrolled in the trial for approximately 6 months]

Clinicians' perceived self-efficacy regarding patient-clinician communication will be assessed using a modified version of the Communication Perceived Self-Efficacy Scale.

Exit interview [after clinician has been enrolled in the trial for approximately 6 months]
Self-efficacy regarding patient-clinician interaction (Patient)
Ramy czasowe: From intervention through 12 months post-intervention

Patients' perceived self-efficacy regarding patient-clinician communication will be assessed using a modified version of the Communication Perceived Self-Efficacy Scale.

From intervention through 12 months post-intervention
Perceived risk (Patient)
Ramy czasowe: From baseline through 12 months post-intervention

Patients' perceived smoking-related disease risks will be assessed using a modified version of the Perceived Susceptibility and Severity Scale.

From baseline through 12 months post-intervention
Outcome expectancies (Patient)
Ramy czasowe: From baseline through 12 months post-intervention

Patients' outcome expectancies regarding tobacco treatment will be assessed using a modified version of the Stanford Expectation of Treatment Scale.

From baseline through 12 months post-intervention
Withdrawal
Ramy czasowe: From baseline through 12 months post-intervention

Withdrawal severity is assessed by Wisconsin Smoking Withdrawal Scale (WSWS).

From baseline through 12 months post-intervention
Side Effects
Ramy czasowe: From baseline through 12 months post-intervention

All reported side effects will be summarized and presented for the study. In addition, the investigators will further identify a pre-specified set of key side effects as being related to drug agonist effects (e.g., nausea, vomiting, racing heart, headache, and sleep disturbance). These will be analyzed as the rate of occurrence during the period of cessation medication use, if applicable.

From baseline through 12 months post-intervention

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Li-Shiun Chen, ScD, MD, MPH, Washington University School of Medicine

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

29 września 2023

Zakończenie podstawowe (Szacowany)

31 marca 2028

Ukończenie studiów (Szacowany)

30 września 2028

Daty rejestracji na studia

Pierwszy przesłany

21 kwietnia 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

4 maja 2023

Pierwszy wysłany (Rzeczywisty)

6 maja 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 202205090
  • 1R01DA056050 (Grant/umowa NIH USA)
  • 5U19CA203654 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

The University will share anonymized human genomic data and relevant associated data from approximately 800 research participants by depositing these data in a NIH-designated data repository or other repositories that meet the appropriate data security measures, confidentiality, privacy, and data use measures. The genotype data will be made available 12 months after trial completion in a NIH-designated data repository after data cleaning and quality control completion, which we anticipate to be in year 5, without restrictions on publication or other dissemination. In addition, information necessary to interpret the submitted data will be included, such as study protocols, data instruments and survey tools.

Ramy czasowe udostępniania IPD

12 months after trial completion

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj